Biotrin Group, owned by Italian diagnostics company DiaSorin, has officially opened a new research, development and manufacturing facility in Dublin which will create up to 40 high-value positions over the next few years.
A developer and manufacturer of diagnostic platform technology, the Biotrin Group announced a new R&D project in June 2010 to develop a molecular diagnostic platform technology and assay reagents for the detection of DNA in infectious disease and oncology.
The new facility will allow the continuation of the R&D activity and the expansion of the manufacturing capability. The total number employed at the facility is expected to reach over 100.
“The investment is highly significant for the Biotrin Group in that it establishes the Biotrin site in Dublin as DiaSorin’s corporate headquarters for molecular diagnostics research, development and manufacturing,” said DiaSorin CEO Dr Carlo Rosa.
Biotrin’s Irish operation was established in Dublin in 1992 to develop and manufacture diagnostic platforms for clinicians and research scientists. It’s a world leader in tests for Human Parovirus B19, a virus that can cause miscarriage in pregnancy.
Article courtesy of siliconrepublic.com